Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition

An anti-tumor drug, the technology of Rubescensin A, applied in the field of medical applications, can solve the problems of increasing anti-cancer effects, etc., and achieve the effects of excellent inhibitory activity, reduced toxicity, and improved inhibitory activity

Active Publication Date: 2015-03-25
SHENZHEN UNIV
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] However, in the prior art, it is difficult to predict which combination of drugs can both increase the efficacy and attenuate the toxicity among the numerous anticancer drugs. In order to increase the anticancer effect and reduce its own toxicity, further in-depth research is needed in this field.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition
  • Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition
  • Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0035] Example: Attenuation and enhancement experiments for various tumor cells and normal human cells

[0036] 1 Materials and methods

[0037] Instruments: (1) American Biotech Epoch microplate spectrophotometer; (2) American Thermo electric carbon dioxide incubator; (3) Singapore ESCO ultra-clean bench; (4) German Memmert water bath.

[0038] Cell lines: 7721 (human liver cancer cells), CFPAC-1 (human pancreatic cancer cells), DU145 (human prostate cancer cells), H441 (human lung cancer cells), HCT116 (human colon cancer cells), Hela (human cervical cancer cells) , MCF-7 (human breast cancer cells), 7701 (normal human liver cells), BEAS-2B (normal human lung epithelial cells), 293A (normal human kidney epithelial cells)

[0039] Dosing concentration: notoginsenoside R7 (50 μmol / L) + oridonin concentration (12.5 μmol / L) ①, notoginseng saponin R7 concentration ① (62.5 μmol / L), oridonin concentration ① (62.5 μmol / L), notoginsenoside R7 (25μmol / L) + oridonin concentration (12...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an antitumor medicament composition with the capabilities of reducing toxicity and enhancing efficacy and application of the antitumor medicament composition. According to the antitumor medicament composition provided by the invention, panax notoginseng saponins R7 and oridonin are active ingredients with the functions of reducing the toxicity and enhancing the efficacy. The antitumor medicament composition has obvious synergistic interaction in various tumor cells and is capable of obviously reducing toxicity to various human normal cells compared with a singly used medicament, reducing damages to an organism and exerting obvious functions of reducing the toxicity and enhancing the efficacy. Due to the specific effects of reducing the toxicity and enhancing the efficacy, the antitumor medicament composition can be widely applied to treating human cancers.

Description

technical field [0001] The invention belongs to the field of medical applications, in particular to an attenuated and synergistic antitumor pharmaceutical composition composed of notoginseng saponin R7 and oridonin A and its application. Background technique [0002] Malignant tumor is a common disease that seriously endangers human health and frequently occurs. According to the report of the World Health Organization, there are more than 10 million new cancer cases and more than 7 million deaths worldwide every year, with more than 5.3 million men and 4.7 million women. Accounted for 12% of deaths, this figure can reach 25% in most developed countries. [0003] In developing countries, due to the acceleration of urbanization, the eating habits and the types of tumors closely related to them are gradually approaching those of economically developed countries. If this trend is not improved, it is expected that by 2020, there will be 15 million new cases worldwide each year;...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P35/00A61K31/352
Inventor 贺震旦张波
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap